Channel Therapeutics Corporation
CHRO · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.38 | -0.19 | -0.34 | 51.15 |
| FCF Yield | -16.21% | -0.35% | -0.57% | -0.58% |
| EV / EBITDA | -4.94 | -40.51 | -170.38 | 0.00 |
| Quality | ||||
| ROIC | 1,434.03% | 132.58% | 73.22% | 32.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.13 | 0.64 | 2.68 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -490.45% | 37.40% | 1.62% | 56.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.22 | -0.17 | -0.30 | 0.00 |
| Interest Coverage | 9.63 | -13.23 | -16.51 | -3,316.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -653.88 | -2,789.63 | -4,505.28 |